Target intelligence / Profile preview

Mycobacterial ribosome

Molecular classification
Ribosome (Prokaryotic), Ribonucleoprotein complex, Translation machinery
01

Overview

The mycobacterial ribosome is a 70S ribonucleoprotein complex composed of a small (30S) and large (50S) subunit, each assembled from unique ribosomal RNAs and proteins. While its fundamental role in protein translation is conserved across bacteria, recent high-resolution structures have shown distinct features characteristic to mycobacteria, such as unique extensions in rRNAs and ribosomal proteins (e.g., H54a insertion, bL27 interactions, and mycobacteria-specific proteins like bS22 and bL37)[1][3][4]. These adaptations affect translation dynamics, stress responses, and contribute to mechanisms like ribosome hibernation during dormancy—facilitated by factors such as RafH (a hypoxia-induced hibernation-promoting factor), which protects the ribosome and modifies susceptibility to antibiotic inhibitors[2][3][5]. These species-specific structural differences not only underpin essential survival pathways in pathogenic mycobacteria but also provide selective targets for antimycobacterial drug design.

Other names
70S ribosome (prokaryotic ribosome)Msm ribosome (Mycobacterium smegmatis ribosome)Mtb ribosome (Mycobacterium tuberculosis ribosome)
02

Mechanism of action

Inhibition of protein synthesis by binding to ribosomal RNA or proteins, blocking initiation, elongation, or termination steps; Inducing ribosome stalling or dysfunction

03

Biological functions

Protein synthesis (translation)Stress response (hibernation, dormancy)
04

Disease associations

Infection (tuberculosis, mycobacterial infection)
05

Safety considerations

Toxicity of ribosome-targeted drugs due to off-target effects in host cells (especially mitochondrial ribosomes)Development of drug resistance via mutations in ribosomal RNA or proteinsSpecificity challenges due to conserved ribosomal core between bacteria and host mitochondria
06

Interacting drugs

Aminoglycosides (streptomycin, kanamycin, amikacin, etc.)

6 more in the full profile.

Beyond the preview

Go deeper on Mycobacterial ribosome.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mycobacterial ribosome.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call